A review on potential of PARP inhibitors in the treatment of prostate cancer

A review on potential of PARP inhibitors in the treatment of prostate cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.

Dades bibliogràfiques
Autor principal:	Islam, Saidul
Altres autors:	Sharmin, Shahana
Format:	Thesis
Idioma:	English
Publicat:	Brac University 2022
Matèries:	Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer > Treatment Enzyme inhibitors > Therapeutic use Cancer > Gene therapy
Accés en línia:	http://hdl.handle.net/10361/17308

Ítems similars

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
per: Karim, Azrin
Publicat: (2024)

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
per: Flora, Sanzida Alam
Publicat: (2024)

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
per: Meem, Manila
Publicat: (2023)

Benign Prostatic Hyperplasia & Prostate Cancer: a review on the treatment strategies
per: Alam, Tahera
Publicat: (2024)

RIPK pathway, as a potential target, for cancer treatment - a review
per: Jahan, Nusrat
Publicat: (2024)

Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
per: Ahmed, Nafisa
Publicat: (2023)

Immunotherapy in the Management of Lung Cancer
per: Tasnim, Humayra
Publicat: (2022)

A review on triple-negative breast cancer and its potential treatment
per: Niasa, Jannatul Ferdous
Publicat: (2023)

Stem cells as therapeutic carrier in cancer treatment
per: Anika, Mysha Yeasmin
Publicat: (2022)

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
per: Hasan, Amit
Publicat: (2024)

Drug repurposing: potential of Antimicrobial Drugs in Breast Cancer Treatment
per: Chakraborty, Anuradha
Publicat: (2024)

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
per: Khan, Muidul Hasan
Publicat: (2024)

A review on potential role of cannabinoids as therapeutic agents in different types of cancer
per: Roy, Hredita
Publicat: (2018)

Recent advances in Cancer treatment targeting autophagy and future aspects
per: Emon, Kamrul Hasan
Publicat: (2022)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
per: Mirza, Maisa Tasnim
Publicat: (2023)

Role of toll-like receptors in cancer immunotherapy– a review
per: Khan, Rezia Nowrin
Publicat: (2021)

In silico analysis revealed hsa-miR-19a-3p and hsa-miR-19b-3p as two potential inhibitors of EGF mRNA in Breast Cancer
per: Nuha, Nabiha Tahsin
Publicat: (2024)

Role of statins as antagonists of SPARC in gastric cancer
per: Shahmat, Rad
Publicat: (2019)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
per: Sorno, Rubina Haque
Publicat: (2024)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
per: Ratu, Tabassum
Publicat: (2024)

A review on bispecific antibody (blinatumomab) for the treatment of acute lymphoblastic leukemia
per: Choki, Kinley
Publicat: (2024)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
per: Razna, Amrin Islam
Publicat: (2019)

A comprehensive review on drug repurposing in cancer treatment
per: Sarkar, Onusree
Publicat: (2024)

A review on RNAi technology and its therapeutic potential in Cancer
per: Mahaleka, Aarshi
Publicat: (2024)

Prevalence and application of an evolving genome editing tool “CRISPR/Cas System” in cancer research and treatment
per: Shaikat, Mahdi Mubin
Publicat: (2023)

Genetic innovations for breast cancer treatment : a review of gene therapy strategies and future implications
per: Hasan, Sakib
Publicat: (2024)

Survey on patients undergoing treatments for cervical, endometrial and ovarian cancer
per: Nawar, Anika
Publicat: (2019)

Statistics and informatics in molecular cancer research

Identification of FAP inhibitors using in silico simulation study
per: Deeba, Maliha Tasnim
Publicat: (2018)

Targeting BRAFV600E in the treatment of CRC
per: Roja, Mashwiyat Samrin
Publicat: (2024)

Targeted therapeutic options in the treatment of Breast Cancer
per: Alam, Kazi Tasnuva
Publicat: (2022)

Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis
per: Rahman, Sanjida
Publicat: (2024)

Biosimilar in lymphoma treatment
per: Tanisha, Mehrin Haque
Publicat: (2021)

Current practice and approaches of immunotherapy in Cancer treatment
per: Khondokar, Faiza
Publicat: (2022)

A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
per: Islam, Nahidul
Publicat: (2023)

A review on Single Nucleotide Polymorphism (SNPs) and their effect on cancer risk in South Asian population
per: Beruni, Sajid Mahmud Al
Publicat: (2022)

Oncogenes: new targets in cancer treatment
per: Chowdhury, Waseka Shams
Publicat: (2020)

Potential phytochemicals and dietary components for the prevention and treatment of skin cancer: A review
per: Muntaha, Habibatul
Publicat: (2023)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
per: Haque, Mushfiqul
Publicat: (2019)

Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
per: Karim, Samia Binte
Publicat: (2024)